Skip to search boxSkip to navigationSkip to main content

Sustained persistence of il2 signaling enhances the antitumor effect of peptide vaccines through t-cell expansion and preventing pd-1 inhibition

  • Hussein Sultan
    ,
  • Takumi Kumai
    ,
  • Valentyna I. Fesenkova
    ,
  • Aaron E. Fan
    ,
  • Juan Wu
    ,
  • Hyun II Cho
*Corresponding author for this work
Scholary Output:
Contribution to journal
Article
Research
Peer-review

Open access

Sustainable Development Goals

  • SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well

Abstract

Peptide vaccines can be a successful and cost-effective way of generating T-cell responses against defined tumor antigens, especially when combined with immune adjuvants such as poly-IC. However, strong immune adjuvants can induce a collateral increase in numbers of irrelevant, nonspecific T cells, which limits the effectiveness of the peptide vaccines. Here, we report that providing prolonged IL2 signaling in the form of either IL2/ anti-IL2 complexes or pegylated IL2 overcomes the competitive suppressive effect of irrelevant T cells, allowing the preferential expansion of antigen-specific T cells. In addition to increasing the number of tumor-reactive T cells, sustained IL2 enhanced the ability of T cells to resist PD-1–induced negative signals, increasing the therapeutic effectiveness of the vaccines against established tumors. This vaccination strategy using peptides and sustained IL2 could be taken into the clinic for the treatment of cancer.

Publication Information

Output type

Scholary Output:
Contribution to journal
Article
Research
Peer-review

Original language

English (US)

Pages from-to (Number of pages)

Pages 617-627 (11 pages)

Journal (Volume, Issue Number)

Cancer Immunology Research (Volume 6, Issue 5)

Publication milestones

  • Published - 05/2018

Publication status

Published - 05/2018

ISSN

2326-6066

Publication IDs

  • Scopus: 85047739784
  • PubMed: 29483127

Publication metrics

Metrics

Scopus
citations
SciVal
citations
4
Fractional count
3
Fractional count
0.33
Fractional count
6
Fractional count
0.67
Fractional count
3
Fractional count
1
SciVal
FWCI
0.33
SciVal
Author count
9
SciVal
Paper percentile
62

PlumX, opens in new tab

Citation count
16
Mentions
3
Captures
46

Funding Details

This work was supported by a grant from the NCI (R01CA157303) and by start-up funds from Augusta University, Georgia Cancer Center, and the Georgia Research Alliance.
FundersFunding number
Georgia Cancer Center Breast Cancer Research Awards
-
NCI
R01CA157303
GRA
-
NCI
-Augusta University-